Critical Contrast: Can-Fite BioPharma (NYSE:CANF) vs. Nexentis Technologies (NASDAQ:NXTS)

Nexentis Technologies (NASDAQ:NXTS) and Can-Fite BioPharma (NYSE:CANF) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, earnings, risk, valuation and dividends.

Risk and Volatility

Nexentis Technologies has a beta of 1.84, meaning that its stock price is 84% more volatile than the S&P 500. Comparatively, Can-Fite BioPharma has a beta of 1.16, meaning that its stock price is 16% more volatile than the S&P 500.

Valuation & Earnings

This table compares Nexentis Technologies and Can-Fite BioPharma”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nexentis Technologies	$210,000.00	4.04	-$4.00 million	($96.07)	-0.01
Can-Fite BioPharma	$405,000.00	4.28	-$7.63 million	($14.80)	-0.11

Nexentis Technologies has higher earnings, but lower revenue than Can-Fite BioPharma. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than Nexentis Technologies, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Nexentis Technologies and Can-Fite BioPharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nexentis Technologies	N/A	-304.79%	-178.91%
Can-Fite BioPharma	N/A	N/A	N/A

Analyst Ratings

This is a summary of current recommendations and price targets for Nexentis Technologies and Can-Fite BioPharma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nexentis Technologies	1	0	0	0	1.00
Can-Fite BioPharma	0	1	2	0	2.67

Can-Fite BioPharma has a consensus target price of $44.00, suggesting a potential upside of 2,616.05%. Given Can-Fite BioPharma’s stronger consensus rating and higher probable upside, analysts plainly believe Can-Fite BioPharma is more favorable than Nexentis Technologies.

Institutional & Insider Ownership

61.2% of Nexentis Technologies shares are owned by institutional investors. Comparatively, 21.0% of Can-Fite BioPharma shares are owned by institutional investors. 6.5% of Nexentis Technologies shares are owned by company insiders. Comparatively, 0.8% of Can-Fite BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Can-Fite BioPharma beats Nexentis Technologies on 8 of the 13 factors compared between the two stocks.

About Nexentis Technologies

N2OFF, Inc., an agri-food tech company, engages in the development and sale of eco-friendly green solutions for the food industry to enhance food safety and shelf life of fresh produce. Its products are based on proprietary blend of food acids combined with various oxidizing agent-based sanitizers and low concentrated fungicides for cleaning, sanitizing, and controlling pathogens on fresh produce that are safer for human consumption and extend their shelf life by reducing their decay. The company’s products include SavePROTECT or PeroStar, a processing aid for post-harvest application that is added to fruit and vegetable wash water; and SF3HS and SF3H, a post-harvest cleaning and sanitizing solution to control plant and foodborne pathogens. It also offers SpuDefender for controlling post-harvest potato sprouts; and FreshProtect to control spoilage-creating microorganisms on post-harvest citrus fruit. The company was formerly known as Save Foods, Inc. and changed its name to N2OFF, Inc. in March 2024. N2OFF, Inc. was incorporated in 2009 and is headquartered in Hod HaSharon, Israel.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.